KUALA LUMPUR, Feb 7 (Bernama) -- Medidata, a Dassault Systèmes company, has been positioned as a Leader in the IDC MarketScape “Worldwide Life Science R&D Risk-Based Monitoring Solutions 2022 Vendor Assessment”.
The IDC MarketScape assessment evaluated Medidata’s comprehensive Risk-Based Quality Management (RBQM) capabilities including Medidata Detect, which provides clinical operations teams with the ability to proactively monitor and mitigate risks to data integrity and patient safety.
“Our position in the IDC MarketScape comes from the success our customers gain with Medidata’s industry-leading analytics, Detect, and our Professional Services offering.
“Clinical trials are faster and have vastly more data than ever before, requiring a seismic shift in how clinical operations and data management teams can–and should–monitor and analyse those data to derive actionable insights,” said Medidata AI senior vice president, Fareed Melhem in a statement.
Medidata Detect is the end-to-end data and risk surveillance platform, providing cross-functional operational teams with the ability to identify, document, monitor and mitigate risks to data integrity and patient safety.
Detect users have access to role-based activities and workflows supported by real-time data, visualisations, and automated insights for better planning and increased efficiency.
As with all of its solutions, RBQM customers are supported by the Medidata Professional Services team that supports rapid implementation and client enablement, process improvements, change management, business transformation and plays a critical role in return of investment (ROI) maximisation.
Headquartered in New York City with offices worldwide to meet the needs of its customers, Medidata is leading the digital transformation of life sciences, creating hope for millions of patients.
-- BERNAMA
No comments:
Post a Comment